BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, Alikhani A, Hedayatizadeh Omran A, Saeedi M, Merat S, Wentzel H, Garratt A, Levi J, Simmons B, Hill A, Tirgar Fakheri H. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020;75:3373-3378. [PMID: 32812025 DOI: 10.1093/jac/dkaa332] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao MZ, Zhao C, Tu SS, Wei XX, Shang HC. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. J Integr Med 2021;19:317-26. [PMID: 33789839 DOI: 10.1016/j.joim.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Han YJ, Lee KH, Yoon S, Nam SW, Ryu S, Seong D, Kim JS, Lee JY, Yang JW, Lee J, Koyanagi A, Hong SH, Dragioti E, Radua J, Smith L, Oh H, Ghayda RA, Kronbichler A, Effenberger M, Kresse D, Denicolò S, Kang W, Jacob L, Shin H, Shin JI. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics 2021;11:1207-31. [PMID: 33391531 DOI: 10.7150/thno.48342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
3 Li J, Liu S, Shi J, Wang X, Xue Y, Zhu HJ. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. ACS Pharmacol Transl Sci 2021;4:870-87. [PMID: 33855276 DOI: 10.1021/acsptsci.1c00016] [Reference Citation Analysis]
4 Mongia A, Saha SK, Chouzenoux E, Majumdar A. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci Rep 2021;11:9047. [PMID: 33907209 DOI: 10.1038/s41598-021-88153-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen C, Weng T, Chen Y, Kao JH, Chao C. Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2103539] [Reference Citation Analysis]
6 Atyabi SMH, Rommasi F, Ramezani MH, Ghane Ezabadi MF, Arani MA, Sadeghi MH, Ahmed MM, Rajabi A, Dehghan N, Sohrabi A, Seifi M, Nasiri MJ. Relationship between blood clots and COVID-19 vaccines: A literature review. Open Life Sciences 2022;17:401-15. [DOI: 10.1515/biol-2022-0035] [Reference Citation Analysis]
7 Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, Morozova I, Kalachikov S, Kirchdoerfer RN, Russo JJ. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect 2020;8:e00674. [PMID: 33124786 DOI: 10.1002/prp2.674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A, Khosravi Shadmani F, Bozorgomid A, Zamanian MH, Afsharian M. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother 2021;76:2158-67. [PMID: 34037760 DOI: 10.1093/jac/dkab152] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect 2021:S1684-1182(21)00135-3. [PMID: 34253490 DOI: 10.1016/j.jmii.2021.05.011] [Reference Citation Analysis]
10 Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko JJ, Zeraatkar D, Agoritsas T, Burns K, Fernando SM, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora MA, Murthy S, Yepes-Nuñez JJ, Vandvik PO, Ye Z, Rochwerg B. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. J Clin Epidemiol 2021;139:68-79. [PMID: 34274489 DOI: 10.1016/j.jclinepi.2021.07.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. J Infect 2021;82:e34-5. [PMID: 33373651 DOI: 10.1016/j.jinf.2020.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu C, Qie M, Hu X, Wang H, Fang G, Wang S. Construction of a piezoelectric immunosensor for ultra-sensitive and highly selective detection of ribavirin in animal-derived foods. Anal Methods 2022. [PMID: 35703169 DOI: 10.1039/d2ay00771a] [Reference Citation Analysis]
13 Aslan AT, Akova M. Current status of therapeutic alternatives for COVID-19: A narrative review. Infez Med 2021;29:312-27. [PMID: 35146336 DOI: 10.53854/liim-2903-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Bokharee N, Khan YH, Khokhar A, Mallhi TH, Alotaibi NH, Rasheed M. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Rev Anti Infect Ther 2021;:1-26. [PMID: 33719819 DOI: 10.1080/14787210.2021.1902805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bassetti M, Corcione S, Dettori S, Lombardi A, Lupia T, Vena A, De Rosa FG, Gori A, Giacobbe DR. Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med 2021;15:985-92. [PMID: 33962524 DOI: 10.1080/17476348.2021.1927719] [Reference Citation Analysis]
16 Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J 2021:postgradmedj-2021-140287. [PMID: 34103373 DOI: 10.1136/postgradmedj-2021-140287] [Reference Citation Analysis]
19 Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, Kane B, Keesari PR, Pulakurthi YS, Sheffels E, Balasubramanian P, Chibbar R, Chittajallu S, Cowie K, Karon J, Siegel L, Tarchand R, Zinn C, Gupta N, Kallmes KM, Saravu K, Touchette J. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22:107. [PMID: 35100985 DOI: 10.1186/s12879-022-07068-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
20 Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghighat E, Mahdavi M, Larijani B. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. Daru 2021;29:449-67. [PMID: 34762250 DOI: 10.1007/s40199-021-00422-8] [Reference Citation Analysis]
21 Wang D, Chen L, Wang L, Hua F, Li J, Li Y, Zhang Y, Fan H, Li W, Clarke M. Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. J Clin Epidemiol 2021:S0895-4356(21)00205-5. [PMID: 34224834 DOI: 10.1016/j.jclinepi.2021.06.027] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Welte T, Ambrose LJ, Sibbring GC, Sheikh S, Müllerová H, Sabir I. Current evidence for COVID-19 therapies: a systematic literature review. Eur Respir Rev 2021;30:200384. [PMID: 33731328 DOI: 10.1183/16000617.0384-2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
23 Kumar P, Kulkarni A, Sharma M, Rao PN. Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19. J Clin Exp Hepatol 2021;11:273-5. [PMID: 33071519 DOI: 10.1016/j.jceh.2020.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel) 2021;14:736. [PMID: 34451833 DOI: 10.3390/ph14080736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kim SB, Ryoo S, Huh K, Joo EJ, Kim YJ, Choi WS, Kim YJ, Yoon YK, Heo JY, Seo YB, Jeong SJ, Park DA, Yu SY, Lee HJ, Kim J, Jin Y, Park J, Peck KR, Choi M, Yeom JS; Korean Society of Infectious Diseases (KSID). Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. Infect Chemother 2021;53:166-219. [PMID: 34409790 DOI: 10.3947/ic.2021.0303] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Khani E, Khiali S, Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol 2021;61:429-60. [PMID: 33511638 DOI: 10.1002/jcph.1822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
27 Khalili H, Nourian A, Ahmadinejad Z, Emadi Kouchak H, Jafari S, Dehghan Manshadi SA, Rasolinejad M, Kebriaeezadeh A. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed 2020;91:e2020102. [PMID: 33525212 DOI: 10.23750/abm.v91i4.10877] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
28 Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, Levi J, Hill A, Shamshirian A. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021;76:753-7. [PMID: 33338232 DOI: 10.1093/jac/dkaa501] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
29 Shoaib MH, Ahmed FR, Sikandar M, Yousuf RI, Saleem MT. A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. Front Pharmacol 2021;12:576448. [PMID: 33732150 DOI: 10.3389/fphar.2021.576448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kow CS, Javed A, Ramachandram D, Hasan SS. Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Rev Anti Infect Ther 2021;:1-9. [PMID: 34719324 DOI: 10.1080/14787210.2022.2000861] [Reference Citation Analysis]
31 Liatsos GD. Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19): 5135-5178 [PMID: 34307564 DOI: 10.12998/wjcc.v9.i19.5135] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61 [PMID: 33816150 DOI: 10.5501/wjv.v10.i2.53] [Reference Citation Analysis]
33 Qiu R, Li J, Xiao Y, Gao Z, Weng Y, Zhang Q, Wang C, Gong H, Li W. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25532. [PMID: 33879694 DOI: 10.1097/MD.0000000000025532] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Abbass S, Kamal E, Salama M, Salman T, Sabry A, Abdel-Razek W, Helmy S, Abdelgwad A, Sakr N, Elgazzar M, Einar M, Farouk M, Saif M, Shehab I, El-Hosieny E, Mansour M, Mahdi D, Tharwa ES, Salah M, Elrouby O, Waked I. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol 2021. [PMID: 34379337 DOI: 10.1002/jmv.27264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Zhaori G, Lu L, Liu C, Guo Y. Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. Pediatr Investig 2020;4:263-74. [PMID: 33376954 DOI: 10.1002/ped4.12227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Tian X, Gan W, Nie Y, Ying R, Tan Y, Chen J, Chen M, Zhang C. Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis. BMJ Open 2021;11:e051484. [PMID: 34244286 DOI: 10.1136/bmjopen-2021-051484] [Reference Citation Analysis]
37 Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, Holgersson J, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen JC. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One 2021;16:e0248132. [PMID: 33705495 DOI: 10.1371/journal.pone.0248132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
38 Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, Ebrahimzadeh A, Azarkar Z, Mansour-Ghanaei F, Joukar F, Yeganeh S, Yaghubi Kalurazi T, Naghipour M, Mehrabi Z, Bahadori AR, Yaghoubi S, Moslemi R, Abbaspour Kasgari H, Fakheri H, Moghimi M, Shabani AM, Nekoukar Z, Babamahmoodi F, Davoudi Badabi AR, Davoodi L, Hassaniazad M, Barahimi E, Tousi A, Sadeghi A, Hosamirudsari H, Ali Asgari A, Abdollahi M, Anushiravani A, Shabani M, Shokouhi S, Khajavirad N, Salehi M, Dehghan Manshadi SA, Mousavi H, Zolfaghari F, Azimi E, Zeinali A, Akbarpour E, Merat D, Eslami G, Mousaviasl S, Sayar S, Radmanesh E, Ebrahimzadeh M, Arizavi Z, Jelvay S, Salmanzadeh S, Esmaeilian H, Mobarak M, Karimi J, Poormontaseri Z, Hasooni Bahrini N, Bonyadi A, Dehghani F, Mirzaei H, Noori Jangi M, Pourmasoomi H, Rezaie Keikhaie L, Afshari M, Nateghi Baygi A, Nateghi Baygi H, Levi J, McCann K, Wentzel H, Simmons B, Hill A, Merat S. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2021:dkab433. [PMID: 34849957 DOI: 10.1093/jac/dkab433] [Reference Citation Analysis]
39 Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, Bernardi FF, Racagni G, Berrino L, Castaldo G, Coscioni E, Rossi F, Capuano A. Therapeutic strategies to fight COVID-19: Which is the status artis? Br J Pharmacol 2021. [PMID: 33960398 DOI: 10.1111/bph.15452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
40 M Mansour S, N Shamma R, A Ahmed K, A Sabry N, Esmat G, A Mahmoud A, Maged A. Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. Int Immunopharmacol 2021;99:108004. [PMID: 34333358 DOI: 10.1016/j.intimp.2021.108004] [Reference Citation Analysis]
41 Sezer A, Halilović-Alihodžić M, Vanwieren AR, Smajkan A, Karić A, Djedović H, Šutković J. A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. J Genet Eng Biotechnol 2022;20:78. [PMID: 35608704 DOI: 10.1186/s43141-022-00353-0] [Reference Citation Analysis]